European guidelines on heart failure: pharmacotherapy

The new 2021 guidelines of the European Society of Cardiology (ESC) have broken with the old step by step treatment of heart failure and have fundamentally revised the strategy in the pharmacotherapy setting. For patients with heart failure and reduced ejection fraction ≤ 40%, the 4 substance groups...

Full description

Saved in:
Bibliographic Details
Published in:Herz 2023-03, Vol.48 (2), p.89
Main Authors: Grundmann, Sebastian, von Zur Mühlen, Constantin
Format: Article
Language:ger
Subjects:
Angiotensin Receptor Antagonists - therapeutic use
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Cardiology
Heart Failure - drug therapy
Humans
Mineralocorticoid Receptor Antagonists - therapeutic use
Stroke Volume
Ventricular Dysfunction, Left - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The new 2021 guidelines of the European Society of Cardiology (ESC) have broken with the old step by step treatment of heart failure and have fundamentally revised the strategy in the pharmacotherapy setting. For patients with heart failure and reduced ejection fraction ≤ 40%, the 4 substance groups angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor-neprilysin inhibitors (ARNI), beta blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucose transporter 2 (SGLT2) inhibitors are now recommended as early as possible after diagnosis. Completing the substance groups has priority over increasing the dosage of the individual substances. This makes it necessary to rethink current clinical practice, especially as the guidelines are reluctant to give concrete instructions for implementation.
ISSN:1615-6692
DOI:10.1007/s00059-022-05157-z